Search results for "aging"

showing 10 items of 10496 documents

Quantitative determination of tumor platinum concentration of patients with advanced Breast, lung, prostate, or colorectal cancers undergone platinum…

2017

Context: Previous studies have reported direct relationship between tumor reduction and its platinum concentration following platinum-based (Pt-based) chemotherapy. However, quantitative data of tumor platinum concentration have not yet been reported for the most common cancers. Aims: Determination of tumor platinum concentration of breast, lung, prostate, and colorectal cancers after Pt-based chemotherapy; and evaluation of the influence of chemo drug type, chemotherapy regimen, and time lapse from last chemotherapy on tumor platinum concentration. Materials and Methods: Tumor samples of patients with advanced breast, lung, prostate, and colorectal cancers undergone Pt-based chemotherapy w…

0301 basic medicineOncologyMalemedicine.medical_specialtyLung NeoplasmsColorectal cancermedicine.medical_treatmentcolorectal cancerBreast Neoplasmsplatinum concentrationlcsh:RC254-28203 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerBreast cancerDrug TherapyProstateInternal medicineNeoplasmsmedicineHumansRadiology Nuclear Medicine and imagingLung cancerPlatinumChemotherapybusiness.industryProstatic NeoplasmsGeneral Medicinemedicine.diseaseprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenRegimenlung cancer030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemalebusinessColorectal NeoplasmsJournal of cancer research and therapeutics
researchProduct

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

2019

Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.The AGO-CaRE-1 study multicenter database was used for analysis. LNR was defined as ratio of number of positive lymph nodes (LN) to the number of resected. Previously established LNR risk groups were used to stratify patients. LNR was investigated with respect to clinical parameters. Univariate and multivariable survival analyses were performed to assess the value of LNR in order to predict overall (OS…

0301 basic medicineOncologyMalemedicine.medical_specialtyMedizinInguinal lymphadenectomyRisk AssessmentVulva03 medical and health sciences0302 clinical medicineRisk groupsPredictive Value of TestsInternal medicineNodal statusGermanymedicineHumansIn patientLymph nodeAgedNeoplasm StagingRetrospective StudiesVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle Agedmedicine.diseasePrognosisSurvival Analysis030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionFemaleLymphLymph NodesbusinessGynecologic oncology
researchProduct

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

2019

A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and patients are at risk of being undertreated or even overtreated with chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful tool to better detect risk of relapse.One hundred and fifty patients diagnosed with localized CC were prospectively enrolled in our study. Tumor tissue from those patients was sequenced by a custom-targeted next-generation sequencing (NGS) panel to characterize somatic mutations. A minimum varian…

0301 basic medicineOncologyMalemedicine.medical_specialtyNeoplasm ResidualColorectal cancerColonmedicine.medical_treatmentPathological stagingConcordanceDNA Mutational AnalysisKaplan-Meier EstimateAdenocarcinomaDisease-Free Survivallaw.inventionCirculating Tumor DNA03 medical and health sciences0302 clinical medicineGene FrequencylawInternal medicineBiomarkers TumorMedicineHumansDigital polymerase chain reactionPostoperative PeriodProspective StudiesPolymerase chain reactionColectomyAgedChemotherapybusiness.industryHazard ratioHigh-Throughput Nucleotide SequencingHematologymedicine.diseaseMinimal residual disease030104 developmental biologyOncology030220 oncology & carcinogenesisColonic NeoplasmsMutationFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast ca…

2017

Abstract Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Resul…

0301 basic medicineOncologyReceptor ErbB-2chemistry.chemical_compoundErbB-20302 clinical medicineDose-intensityExemestane80 and overNeoplasm MetastasisFulvestrantAged 80 and overeducation.field_of_studyAdvanced breast cancer Dose-intensity Everolimus Fulvestrant Hormone-receptor positiveAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2; SurgeryGeneral MedicineMiddle AgedEverolimu030220 oncology & carcinogenesisAdvanced breast cancerFemaleAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; SurgeryReceptormedicine.drugAdultmedicine.medical_specialtyPopulationSocio-culturaleBreast NeoplasmsHormone-receptor positive03 medical and health sciencesBreast cancerAdvanced breast cancer; Dose-intensity; Everolimus; Fulvestrant; Hormone-receptor positive; Adult; Aged; Aged 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor ErbB-2Internal medicinemedicineHumansEverolimusAdverse effecteducationAgedNeoplasm StagingGynecologyEverolimusFulvestrantbusiness.industryfungiCancermedicine.diseaseAndrostadienesClinical trial030104 developmental biologychemistrySurgerybusinessFollow-Up StudiesThe Breast
researchProduct

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

2016

Abstract Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-sp…

0301 basic medicineOncologySettore MED/42 - Igiene Generale E Applicata0302 clinical medicinemorphology80 and overStage (cooking)Aged 80 and overOvarian Neoplasmseducation.field_of_studyepidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and GynecologyObstetrics and Gynecologyepidemiology; histology; morphology; ovarian cancer; stage; survivalMiddle AgedTransitional cell carcinomaovarian cancerOncology030220 oncology & carcinogenesisClear cell carcinomaepidemiologyFemaleHumanAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturalesurvivalArticlehistology03 medical and health sciencesInternal medicinemedicineHumansovarian cancer epidemiology survival stage morphology histologyeducationepidemiology ; histology ; morphology ; ovarian cancer ; stage ; survivalCancer stagingAgedNeoplasm StagingGynecologybusiness.industryOvarian NeoplasmCancermedicine.diseasestageCancer registry030104 developmental biologyOvarian cancerbusiness
researchProduct

Current molecular and clinical insights into uveal melanoma (Review)

2021

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an incidence of approximately 5 cases per million individuals annually in the United States, UM could be considered a relatively rare cancer. The 90.95% of UM cases arise from the choroid. Diagnosis is based mainly on a clinical examination and ancillary tests, with ocular ultrasonography being of greatest value. Differential diagnosis can prove challenging in the case of indeterminate choroidal lesions and, sometimes, monitoring for documented growth may be the proper approach. Fine needle aspiration biopsy tends to be performed with a prognostic purpose, often in combination with radiotherapy. Gene expres…

0301 basic medicineOncologyUveal NeoplasmsCancer Researchmedicine.medical_specialtydiagnosisEnucleationBiology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisGrading (tumors)MelanomaBiomarkers; Diagnosis; Epigenetics; Prognosis; Staging; Treatment; Uveal melanomamedicine.diagnostic_testtreatmentepigeneticsMelanomaGene Expression ProfilingCancerbiomarkersArticlesstagingmedicine.diseasePrognosisPrimary tumor030104 developmental biologyFine-needle aspirationOncology030220 oncology & carcinogenesisMutationDifferential diagnosisuveal melanomaGNAQ
researchProduct

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin

2015

Oral fluoropyrimidines have been available for more than 10 years. Capecitabine is well established in treating solid tumors in Europe. S-1 (Teysuno®), an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and oteracil, has not been available in non-Asia countries until recently. In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer. In Europe, the first trials with S-1 were disappointing due to high unacceptable incidences of adverse events. Pharmacokinetic studies showed differences in Asian and Caucasian patients; therefore, a new non-Asian study program was initiated,…

0301 basic medicineOncologymedicine.medical_specialtyAdministration OralAntineoplastic AgentsTegafurCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineDrug DiscoverymedicineClinical endpointHumansPharmacology (medical)Survival rateNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerGeneral Medicinemedicine.diseaseHematologic DiseasesSurvival Rate030104 developmental biologyInfectious DiseasesOncologyTolerability030220 oncology & carcinogenesisDrug Therapy CombinationFluorouracilCisplatinbusinessmedicine.drugTegafur/gimeracil/oteracilChemotherapy
researchProduct

A free radical theory of frailty.

2018

The free radical theory of ageing provided an intellectual framework for many laboratories working on ageing. However, experimental and clinical evidence showing that high doses of antioxidants do not have an effect on ageing or on age-associated diseases, cast doubts on the validity of this theory. Data from our own laboratory show that oxidative damage does not correlate with age, especially in the geriatric population, but rather with the frailty state. This has led us to postulate the free radical theory of frailty that proposes that oxidative damage is associated with frailty, but not with chronological age itself. Superoxide dismutase deficient mice are more frail than controls. But m…

0301 basic medicineOncologymedicine.medical_specialtyAgingFree Radicalsmedicine.disease_causeBiochemistrySuperoxide dismutase03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineDeficient mouseHigh dosesMedicineAnimalsHumansFree-radical theory of agingGeriatricsbiologyFrailtybusiness.industryChronological ageOxidative Stress030104 developmental biologyAgeingbiology.proteinbusiness030217 neurology & neurosurgeryOxidative stressFree radical biologymedicine
researchProduct

Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer’s Disease and Chronic Progressive Multiple Sclerosis: A Review

2020

Background: Reducing the burden of beta-amyloid accumulation and toxic autoimmunity-related proteins, one of the recognized pathophysiological markers of chronic and common neurological disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS), may be a valid alternative therapy to reduce their accumulation in the brain and thus reduce the progression of these disorders. The objective of this review was to evaluate the efficacy of plasmapheresis (PP) in AD and chronic progressive MS patients (in terms of improving clinical symptoms) and to analyze its safety and protocols. Methods: Articles related to this topic and published without time limitations in the Medline, and C…

0301 basic medicineOncologymedicine.medical_specialtyAmyloid betamedicine.medical_treatmentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441DiseaseReviewlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineVerbal fluency testDementiamagnetic resonance imagingauto-immunityalbuminbiologybusiness.industryMultiple sclerosislcsh:Rmedicine.diseasePathophysiologyamyloid beta030104 developmental biologyplasmapheresisToxicitybiology.proteinMolecular MedicinePlasmapheresisbusiness030217 neurology & neurosurgerydementiaPharmaceuticals
researchProduct

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

2018

Abstract Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread. Two TACE techniques have been used since 2004, convent…

0301 basic medicineOncologymedicine.medical_specialtyCarcinoma Hepatocellular03 medical and health sciences0302 clinical medicineInternal medicineCarcinomamedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Chemoembolization TherapeuticPerformance statusbusiness.industryLiver NeoplasmsCancerGeneral Medicinemedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodolLiver functionLiver cancerbusinessmedicine.drugCancer treatment reviews
researchProduct